|
Oct 5
|
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
|
|
Oct 1
|
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
|
|
Sep 30
|
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 24
|
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
|
|
Jul 15
|
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
|
|
Jun 13
|
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
|
|
May 14
|
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
|
|
May 8
|
Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)
|
|
May 7
|
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
|
|
May 6
|
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
|
Apr 2
|
Pliant Therapeutics to Participate in Upcoming Investor Events
|
|
Mar 27
|
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
|
|
Mar 12
|
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
|
|
Mar 7
|
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
|